Learn how the severity of skin symptoms in psoriatic arthritis relates to joint health, disease progression, and treatment ...

Living with psoriatic arthritis (PsA) can feel overwhelming at times. However, making self-care a regular part of your daily routine can empower you to better manage symptoms and enhance your overall ...

Psoriatic arthritis (PsA) is often misunderstood, and those misconceptions can make it harder for people to recognize symptoms, seek care, or understand what living with the condition is really like.

Ixekizumab plus tirzepatide (IXE+TZP) shows significant benefits over ixekizumab (IXE) alone in adults with active psoriatic arthritis (PsA) who are overweight or have obesity, according to a study ...

European regulators have recommended expansion of the marketing authorization for Sotyktu (deucravacitinib, Bristol-Myers Squibb) to include treatment of active psoriatic arthritis in adults. The new ...

DENVER -- Adding a GLP-1 agonist to psoriasis medication significantly improved outcomes in patients with psoriatic arthritis (PsA) and overweight or obesity, a phase III randomized trial showed.

What Is Sotyktu, and Why Does It Matter? Sotyktu (deucravacitinib) is an oral selective tyrosine kinase 2 (TYK2) inhibitor used to treat autoimmune inflammatory diseases such as plaque psoriasis in ...

In a dizzying span of seven months in 2022, Bristol Myers Squibb gained FDA approval for three new products, touting each with the potential to achieve $4 billion in peak sales. While multiple myeloma ...

Please provide your email address to receive an email when new articles are posted on . Dual therapy with GLP-1s and ixekizumab was associated with improvements in both psoriasis and PsA.

2026 is all about the skinification of hair. And, hey: It makes sense. After all, your scalp is an extension of your skin and deserves equal TLC to your face and body—and the easiest place to start is ...

The results from two recent clinical trials reinforce that treating obesity alongside inflammation can improve quality of life for many people with psoriatic diseases. In clinical trials involving ...

Eli Lilly said on Wednesday its weight-loss drug, Zepbound, used with psoriasis treatment Taltz, showed better results ⁠in patients with the skin disease and obesity in a late-stage study, compared to ...